Sponsors (3)
The bill would target U.S. foreign assistance toward highly cost‑effective maternal and child health interventions—likely saving many lives and strengthening diplomatic ties—but requires increased federal spending, adds administrative burdens, and risks crowding out or misaligning support for other locally needed health services if implementation and partner capacity fall short.
Pregnant women and children in prioritized partner countries would gain expanded access to multiple micronutrient supplements (MMS), prenatal/perinatal care, vaccines, and treatments for diarrhea and pneumonia, likely reducing maternal and child mortality and improving birth and early‑life outcomes.
Focused investment in high‑impact interventions (immunizations, MMS, treatments) produces strong value for money — immunization programs and prioritized MCH interventions are highly cost‑effective and can yield large benefits per dollar invested.
The Act increases transparency, monitoring, and interagency coordination (annual reports, standardized indicators, harmonized budget tags, clearer lead‑agency definitions), improving congressional oversight and the ability to measure program impact and funding use.
Expanding these overseas programs would increase U.S. foreign assistance spending — including up to $150 million/year in authorized funding — meaning higher costs for U.S. taxpayers or trade‑offs with other budget priorities.
Prioritizing MMS and a narrow set of cost‑effective interventions risks diverting funds and attention away from other essential maternal and child health services (skilled birth attendance, obstetric care) and from locally relevant nutrition strategies.
Projected mortality and outcome gains depend on implementation quality and partner‑country health systems; if context, delivery quality, or capacity fall short, the real-world benefits could be substantially lower than modeled estimates.
Based on analysis of 6 sections of legislative text.
Authorizes U.S. strategy, reporting, and up to $150M/year (FY2026–FY2030) to scale maternal and child health interventions—especially MMS prenatal supplements—in priority countries.
Official title: To provide support for scaling up global access to multiple micronutrient supplements and other cost effective maternal and child interventions, and for other purposes.
Introduced July 2, 2026 by Young Kim · Last progress July 2, 2026
Establishes U.S. policy and multi-year strategy to make maternal and child survival a central objective of U.S. global health and foreign assistance, with specific coverage and mortality targets through 2030. Directs the designated foreign assistance agency to prioritize scaling procurement and delivery of multiple micronutrient supplements (MMS) and other proven maternal and child health interventions, requires a 5-year strategy and annual reporting, and authorizes up to $150 million per year for FY2026–FY2030 to support MMS programs in priority countries. Requires selection and periodic update of priority countries, standardized performance indicators and budget codes to track funding and outcomes, and annual congressional reporting for five years on progress, allocations, program reach, coordination, and implementation lessons. Emphasizes cost-effectiveness and ties program outcomes to U.S. foreign policy and national security interests.